Cardiovascular therapy developer Milestone Pharmaceuticals will use proceeds from the Novo-led round to advance its lead candidate to a phase 3 clinical trial.

Milestone Pharmaceuticals, a Canada-based developer of therapies aimed at cardiovascular conditions, raised $55m yesterday in a series C round led by pharmaceutical firm Novo. BDC Capital, the investment arm of state-owned Business Development Bank of Canada, and Fonds de solidarité FTQ, the capital development organisation for Quebec, also took part along with Forbion Capital Partners,…

The rest of this content is only accessible to Subscribers.

This content is only accessible to subscribers. If you are a subscriber, please sign in. Otherwise, if you would like to try before you buy and haven't previously taken out a free trial, you can do so below. You can also see details on subscriptions by clicking the Subscription Options button.